PMID- 35567407
OWN - NLM
STAT- MEDLINE
DCOM- 20220809
LR  - 20220810
IS  - 1365-2141 (Electronic)
IS  - 0007-1048 (Linking)
VI  - 198
IP  - 4
DP  - 2022 Aug
TI  - Outcomes of Hodgkin variant Richter transformation in chronic lymphocytic 
      leukaemia and small lymphocytic lymphoma in British Columbia.
PG  - 684-692
LID - 10.1111/bjh.18241 [doi]
AB  - Hodgkin variant Richter transformation (HvRT) is a rare and challenging 
      complication of chronic lymphocytic leukaemia (CLL) for which information on 
      prognostic factors and treatment approaches remain limited. We analysed 
      characteristics and survival outcomes of a population-based cohort of 32 patients 
      with HvRT identified in British Columbia over a 40-year period. Median interval 
      from CLL diagnosis to HvRT was 5.6 years (range, 0-33.6), with five cases 
      diagnosed concurrently. Most patients (80%) had treatment for CLL prior to HvRT. 
      Median age at HvRT was 71 years (range, 51-86) and the majority of patients had 
      high-risk disease, including stage 3-4 in 87% and International Prognostic Score 
      (IPS) >/= 4 in 65%. Two-year progression-free (PFS) and overall survival (OS) from 
      HvRT were 47% (95% CI: 29%-64%) and 57% (95% CI: 38%-72%), respectively. OS from 
      HvRT was significantly worse in those with anaemia (p = 0.02), elevated lactate 
      dehydrogenase (p = 0.04), high IPS (p = 0.04), and worse performance status 
      (p = 0.001). For those treated with curative-intent ABVD/ABVD-like therapy, 
      2-year PFS and OS were 70% (95% CI: 45%-85%) and 74% (95% CI: 49%-89%), 
      respectively. In this real-world population-based cohort, HvRT was associated 
      with poor clinical outcomes overall; however, those able to tolerate 
      curative-intent therapy had similar survival to older patients with de novo HL.
CI  - (c) 2022 British Society for Haematology and John Wiley & Sons Ltd.
FAU - Zhu, Kai
AU  - Zhu K
AUID- ORCID: 0000-0002-2883-5486
AD  - Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, 
      Canada.
FAU - Jamroz, Andrew
AU  - Jamroz A
AD  - Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, 
      Canada.
AD  - Faculty of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada.
FAU - Huang, Steven
AU  - Huang S
AD  - Leukemia/Bone Marrow Transplant Program of BC and Division of Hematology, BC 
      Cancer, University of British Columbia, Vancouver, British Columbia, Canada.
FAU - Villa, Diego
AU  - Villa D
AUID- ORCID: 0000-0002-4625-3009
AD  - Centre for Lymphoid Cancer and Division of Medical Oncology, BC Cancer, 
      University of British Columbia, Vancouver, British Columbia, Canada.
FAU - Freeman, Ciara L
AU  - Freeman CL
AD  - Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt 
      Cancer Centre, Tampa, Florida, USA.
FAU - Scott, David W
AU  - Scott DW
AUID- ORCID: 0000-0002-0435-5947
AD  - Centre for Lymphoid Cancer and Division of Medical Oncology, BC Cancer, 
      University of British Columbia, Vancouver, British Columbia, Canada.
FAU - Slack, Graham
AU  - Slack G
AD  - Department of Pathology and Laboratory Medicine, BC Cancer, University of British 
      Columbia, Vancouver, British Columbia, Canada.
FAU - Sehn, Laurie H
AU  - Sehn LH
AUID- ORCID: 0000-0003-1860-9765
AD  - Centre for Lymphoid Cancer and Division of Medical Oncology, BC Cancer, 
      University of British Columbia, Vancouver, British Columbia, Canada.
FAU - Connors, Joseph M
AU  - Connors JM
AUID- ORCID: 0000-0002-1361-7531
AD  - Centre for Lymphoid Cancer and Division of Medical Oncology, BC Cancer, 
      University of British Columbia, Vancouver, British Columbia, Canada.
FAU - Toze, Cynthia L
AU  - Toze CL
AD  - Leukemia/Bone Marrow Transplant Program of BC and Division of Hematology, BC 
      Cancer, University of British Columbia, Vancouver, British Columbia, Canada.
FAU - Savage, Kerry J
AU  - Savage KJ
AUID- ORCID: 0000-0002-5835-9863
AD  - Centre for Lymphoid Cancer and Division of Medical Oncology, BC Cancer, 
      University of British Columbia, Vancouver, British Columbia, Canada.
FAU - Gerrie, Alina S
AU  - Gerrie AS
AUID- ORCID: 0000-0003-4727-1425
AD  - Centre for Lymphoid Cancer and Division of Medical Oncology, BC Cancer, 
      University of British Columbia, Vancouver, British Columbia, Canada.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20220514
PL  - England
TA  - Br J Haematol
JT  - British journal of haematology
JID - 0372544
RN  - 11056-06-7 (Bleomycin)
RN  - 5V9KLZ54CY (Vinblastine)
RN  - 7GR28W0FJI (Dacarbazine)
RN  - 80168379AG (Doxorubicin)
SB  - IM
MH  - Antineoplastic Combined Chemotherapy Protocols/adverse effects
MH  - Bleomycin
MH  - British Columbia/epidemiology
MH  - Dacarbazine
MH  - Doxorubicin
MH  - *Hodgkin Disease/drug therapy
MH  - Humans
MH  - *Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy
MH  - *Lymphoma, Large B-Cell, Diffuse/drug therapy
MH  - Prognosis
MH  - Vinblastine
OTO - NOTNLM
OT  - CLL
OT  - Richter-S syndrome
OT  - hodgkins lymphoma
OT  - lymphomas
EDAT- 2022/05/15 06:00
MHDA- 2022/08/10 06:00
CRDT- 2022/05/14 05:52
PHST- 2022/04/23 00:00 [revised]
PHST- 2022/02/12 00:00 [received]
PHST- 2022/04/27 00:00 [accepted]
PHST- 2022/05/15 06:00 [pubmed]
PHST- 2022/08/10 06:00 [medline]
PHST- 2022/05/14 05:52 [entrez]
AID - 10.1111/bjh.18241 [doi]
PST - ppublish
SO  - Br J Haematol. 2022 Aug;198(4):684-692. doi: 10.1111/bjh.18241. Epub 2022 May 14.